Serum level of clozapine and relapse

Therapeutic Drug Monitoring

Volumn 25, Issue 2, 2003, Pages 252-255

  Ulrich, Sven ^a   Wolf, Rainer ^a   Staedt, Juergen ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

Clozapine; Maintenance treatment; Relapse; Schizophrenia; Serum level

Indexed keywords

CLOZAPINE;

ADULT; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; INTOXICATION; MAINTENANCE THERAPY; OUTPATIENT CARE; PARANOID SCHIZOPHRENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; SCHIZOAFFECTIVE PSYCHOSIS;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; PATIENT READMISSION; PSYCHIATRIC DEPARTMENT, HOSPITAL; RECURRENCE; SCHIZOPHRENIA;

EID: 0037381694     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200304000-00019     Document Type: Article

References (18)

1. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN). Praxisleitlinien in Psychiatrie und Psychotherapie, Bd I: Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopf Darmstadt, 1998.
2. Lambert M, Moritz S, Bender S, et al. Therapieresistenz bei schizophrenen Patienten - aktueller Stand. Psychopharmakotherapie. 2001;8:2-17.
3. McEvoy JP, Scheifler PL, Frances A. The expert consensus guideline series: treatment of schizophrenia 1999. J Clin Psychiat. 1999; 60:Suppl 11.
4. Cooper TB. Clozapine plasma level monitoring: current status. Psychiat Quart. 1996;67:297-311.
5. Stevens I, Farger G, Gaertner HJ. Clozapine serum levels. Pharmacopsychiat. 1995;28:219.
6. Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 500 drugs. Pharmazie. 1997;52:895-911.
7. Gaertner I, Gaertner HJ, Vonthein R, et al. Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol. 2001;21:305-310.
8. Liu HC, Chang WH, Wei FC, et al. Monitoring plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther Drug Monit. 1996;18:200-207.
9. Haring C, Neudorfer C, Schwitzer J, et al. EEG alterations in patients treated with clozapine in relation to plasma levels. Psychopharmacol. 1994;114:97-100.
10. Olesen OV, Thomsen K, Jensen PN, et al. Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross sectional study. Psychopharmacol. 1995;117:371-378.
11. Taylor D, Ellison Z, Ementon Shaw L, et al. Co-administration of citalopram and clozapine: effect on plasma clozapine levels. Int Clin Psychopharmacol. 1998;13:19-21.
12. Kashuba ADM, Nafziger AN. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet. 1998;34:203-218.
13. Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiat. 1997;171:109-112.
14. Raaska K, Raitasuo V, Neuvonen PJ. Effect of influenza vaccination on serum clozapine and ist main metabolite concentrations in patients with schizophrenia. Eur J Clin Pharmacol. 2001;57:705-708.
15. Van der Molen-Eijgenraam M, Blanken-Meijs JTHM, Heeringa M, et al. Delirium door stijging van clozapinespiegels tijdens ontstekingsreactie. Ned Tijdschr Geneeskd. 2001;145:427-430.
16. Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiat. 1999;156:876-884.
17. Staedt J, Stoppe G, Hajak G, et al. Rebound insomnia after abrupt clozapine withdrawal. Eur Arch Psychiat Clin Neurosci. 1996;246: 79-82.
18. Baumann P. Pharmacokinetic-pharmacodynamic relationships of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996;31:444-469.